NCX 466

• Description :

  NCX 466 is an orally active COX-1 and COX-2 inhibitor that exhibits anti-inflammatory and analgesic effects. Additionally, NCX 466 acts as a NO donor, exerting anti-inflammatory and antioxidant effects by improving microcirculation. NCX 466 significantly reduces the levels of transforming growth factor-β (TGF-β) and oxidative stress markers (such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) ), and it decreases leukocyte recruitment during inflammation by reducing myeloperoxidase (MPO) activity, thereby preventing bleomycin (HY-108345) -induced pulmonary fibrosis in mice[1].

• UNSPSC :

  12352005

• Target :

  COX; Glutathione Peroxidase; TGF-β Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; TGF-beta/Smad

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ncx-466.html

• Smiles :

  O=C(OCCCC[C@H](O[N+]([O-])=O)CO[N+]([O-])=O)[C@H](C1=CC2=C(C=C(OC)C=C2)C=C1)C

• Molecular Formula :

  C20H24N2O9

• Molecular Weight :

  436.41

• References & Citations :

  [1]Pini A, et al. Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor. J Pharmacol Exp Ther. 2012 May;341 (2) :493-9.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  COX-1; COX-2

• CAS Number :

  [1262956-64-8]